MicroPort Endovascular MedTech Ltd (688016) - Total Liabilities
Based on the latest financial reports, MicroPort Endovascular MedTech Ltd (688016) has total liabilities worth CN¥680.21 Million CNY (≈ $99.54 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of MicroPort Endovascular MedTech Ltd to evaluate the company's liquid asset resilience ratio.
MicroPort Endovascular MedTech Ltd - Total Liabilities Trend (2016–2025)
This chart illustrates how MicroPort Endovascular MedTech Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 688016 total asset value.
MicroPort Endovascular MedTech Ltd Competitors by Total Liabilities
The table below lists competitors of MicroPort Endovascular MedTech Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Flight Centre Travel Group Ltd
AU:FLT
|
Australia | AU$3.47 Billion |
|
YFY Inc
TW:1907
|
Taiwan | NT$82.63 Billion |
|
Anhui Xinhua Media Co Ltd
SHG:601801
|
China | CN¥7.53 Billion |
|
Global Ship Lease Inc
NYSE:GSL
|
USA | $1.04 Billion |
|
ICF International Inc
NASDAQ:ICFI
|
USA | $1.05 Billion |
|
First Tractor Co Ltd
SHG:601038
|
China | CN¥6.66 Billion |
|
IGNITIS GRUPE AB EO 2233
F:IGV0
|
Germany | €3.78 Billion |
|
Pavilion Real Estate Inv Trust
KLSE:5212
|
Malaysia | RM4.34 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down MicroPort Endovascular MedTech Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is MicroPort Endovascular MedTech Ltd's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MicroPort Endovascular MedTech Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MicroPort Endovascular MedTech Ltd (2016–2025)
The table below shows the annual total liabilities of MicroPort Endovascular MedTech Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥-3.98 Billion ≈ $-582.73 Million |
-948.88% |
| 2024-12-31 | CN¥469.13 Million ≈ $68.65 Million |
+22.60% |
| 2023-12-31 | CN¥382.63 Million ≈ $55.99 Million |
+51.54% |
| 2022-12-31 | CN¥252.49 Million ≈ $36.95 Million |
+9.08% |
| 2021-12-31 | CN¥231.47 Million ≈ $33.87 Million |
+62.90% |
| 2020-12-31 | CN¥142.09 Million ≈ $20.79 Million |
+58.34% |
| 2019-12-31 | CN¥89.74 Million ≈ $13.13 Million |
+70.41% |
| 2018-12-31 | CN¥52.66 Million ≈ $7.71 Million |
+45.29% |
| 2017-12-31 | CN¥36.24 Million ≈ $5.30 Million |
-44.43% |
| 2016-12-31 | CN¥65.22 Million ≈ $9.54 Million |
-- |
About MicroPort Endovascular MedTech Ltd
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft syste… Read more